Deerfield invested in the early stage institutional funding and provided a total of $20 million to Editas. Editas is at the forefront of developing CRISPR/Cas9, a genome-editing technology, which makes it possible to turn off or edit disease-causing genes, potentially leading to a cure. The financing will support the advancement of multiple new therapies into studies which can prove their utility.